International Journal of Medical Ophthalmology

International Journal of Medical Ophthalmology

2019, Vol. 1 Issue 1, Part A
Effect of intravitreal Bevacizumab on macular edema secondary to retinal vascular occlusion
Author(s): Dr. Nimish Kumar Singh and Vidya Bhusan Sinha
Abstract:
Objective: To find out the effect of intravitreal injection of Bevacizumab on central macular thickness (CMT) and best corrected visual acuity (BCVA) in cases of retinal vascular occlusion (RVO).
Material and method: All the patients of RVO treated at our institute over a period of 1 year, with a central macular thickness of more than 250µ were included in the study. Intravitreal injection of Bevacizumab was given and the CMT and BCVA were measured after a control period of 1 month. The injection was repeated at intervals of 1.5 months if decrease in CMT was less than 30%.
Result: Out of the total 78 patients there was a significant improvement in BCVAin 58 patients. There was a significant decrease in central macular thickness in all of them.
Conclusion: Anti-VEGF agent Bevacizumab causes significant reduction in central macular thickness and improves BCVA in cases of macular edema secondary to retinal vascular occlusion.
Pages: 23-25  |  546 Views  153 Downloads
Download Full Article: Click Here
How to cite this article:
Dr. Nimish Kumar Singh, Vidya Bhusan Sinha. Effect of intravitreal Bevacizumab on macular edema secondary to retinal vascular occlusion. Int J Med Ophthalmol 2019;1(1):23-25. DOI: 10.33545/26638266.2019.v1.i1a.7
International Journal of Medical Ophthalmology